These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 29992529)

  • 1. MTOR Pathway-Based Discovery of Genetic Susceptibility to L-DOPA-Induced Dyskinesia in Parkinson's Disease Patients.
    Martín-Flores N; Fernández-Santiago R; Antonelli F; Cerquera C; Moreno V; Martí MJ; Ezquerra M; Malagelada C
    Mol Neurobiol; 2019 Mar; 56(3):2092-2100. PubMed ID: 29992529
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SNCA and mTOR Pathway Single Nucleotide Polymorphisms Interact to Modulate the Age at Onset of Parkinson's Disease.
    Fernández-Santiago R; Martín-Flores N; Antonelli F; Cerquera C; Moreno V; Bandres-Ciga S; Manduchi E; Tolosa E; Singleton AB; Moore JH; ; Martí MJ; Ezquerra M; Malagelada C
    Mov Disord; 2019 Sep; 34(9):1333-1344. PubMed ID: 31234232
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cerebrospinal fluid levels of catecholamines and its metabolites in Parkinson's disease: effect of l-DOPA treatment and changes in levodopa-induced dyskinesia.
    Andersen AD; Blaabjerg M; Binzer M; Kamal A; Thagesen H; Kjaer TW; Stenager E; Gramsbergen JBP
    J Neurochem; 2017 May; 141(4):614-625. PubMed ID: 28244186
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DAT gene polymorphisms (rs28363170, rs393795) and levodopa-induced dyskinesias in Parkinson's disease.
    Purcaro C; Vanacore N; Moret F; Di Battista ME; Rubino A; Pierandrei S; Lucarelli M; Meco G; Fattapposta F; Pascale E
    Neurosci Lett; 2019 Jan; 690():83-88. PubMed ID: 30316985
    [TBL] [Abstract][Full Text] [Related]  

  • 5. mTOR inhibition alleviates L-DOPA-induced dyskinesia in parkinsonian rats.
    Decressac M; Björklund A
    J Parkinsons Dis; 2013; 3(1):13-7. PubMed ID: 23938307
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dopamine Pathway and Parkinson's Risk Variants Are Associated with Levodopa-Induced Dyskinesia.
    Sosero YL; Bandres-Ciga S; Ferwerda B; Tocino MTP; Belloso DR; Gómez-Garre P; Faouzi J; Taba P; Pavelka L; Marques TM; Gomes CPC; Kolodkin A; May P; Milanowski LM; Wszolek ZK; Uitti RJ; Heutink P; van Hilten JJ; Simon DK; Eberly S; Alvarez I; Krohn L; Yu E; Freeman K; Rudakou U; Ruskey JA; Asayesh F; Menéndez-Gonzàlez M; Pastor P; Ross OA; Krüger R; ; Corvol JC; Koks S; Mir P; De Bie RMA; Iwaki H; Gan-Or Z;
    Mov Disord; 2024 Oct; 39(10):1773-1783. PubMed ID: 39132902
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of dopamine receptor D3 polymorphism with Levodopa-induced Dyskinesia: A study on Parkinson's disease patients from India.
    Sarkar S; Biswas A; Ansari S; Choudhury S; Banerjee R; Chatterjee S; Dey S; Kumar H
    Neurosci Lett; 2024 Mar; 825():137706. PubMed ID: 38431040
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intranigral administration of substance P receptor antagonist attenuated levodopa-induced dyskinesia in a rat model of Parkinson's disease.
    Yang X; Zhao H; Shi H; Wang X; Zhang S; Zhang Z; Zu J; Zhang W; Shen X; Cui G; Hua F
    Exp Neurol; 2015 Sep; 271():168-74. PubMed ID: 26001615
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [L-dopa induced dyskinesia in Parkinson's disease].
    Bastide MF; Bézard E
    Bull Acad Natl Med; 2015; 199(2-3):201-12. PubMed ID: 27476302
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polymorphisms of Dopamine Receptor Genes and Risk of L-Dopa-Induced Dyskinesia in Parkinson's Disease.
    Comi C; Ferrari M; Marino F; Magistrelli L; Cantello R; Riboldazzi G; Bianchi ML; Bono G; Cosentino M
    Int J Mol Sci; 2017 Jan; 18(2):. PubMed ID: 28125015
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A preclinical study on the combined effects of repeated eltoprazine and preladenant treatment for alleviating L-DOPA-induced dyskinesia in Parkinson's disease.
    Ko WKD; Li Q; Cheng LY; Morelli M; Carta M; Bezard E
    Eur J Pharmacol; 2017 Oct; 813():10-16. PubMed ID: 28739086
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RasGRP1 is a causal factor in the development of l-DOPA-induced dyskinesia in Parkinson's disease.
    Eshraghi M; Ramírez-Jarquín UN; Shahani N; Nuzzo T; De Rosa A; Swarnkar S; Galli N; Rivera O; Tsaprailis G; Scharager-Tapia C; Crynen G; Li Q; Thiolat ML; Bezard E; Usiello A; Subramaniam S
    Sci Adv; 2020 May; 6(18):eaaz7001. PubMed ID: 32426479
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Associations between variants in levodopa metabolic pathway genes and levodopa-induced dyskinesia in Parkinson's disease.
    Yan JH; Ge YL; Wang PZ; Li W; Jin H; Zhang JR; Chen J; Wang F; Li D; Mao CJ; Li K; Liu CF
    Neurosci Lett; 2023 Mar; 801():137140. PubMed ID: 36813078
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Do tardive dyskinesia and L-dopa induced dyskinesia share common genetic risk factors? An exploratory study.
    Greenbaum L; Goldwurm S; Zozulinsky P; Lifschytz T; Cohen OS; Yahalom G; Cilia R; Tesei S; Asselta R; Inzelberg R; Kohn Y; Hassin-Baer S; Lerer B
    J Mol Neurosci; 2013 Oct; 51(2):380-8. PubMed ID: 23666822
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CaMKII inhibition ameliorated levodopa-induced dyskinesia by downregulating tyrosine hydroxylase activity in an experimental model of Parkinson's disease.
    Yang X; Zhu Z; Ding X; Wang X; Cui G; Hua F; Xiang J
    Brain Res; 2018 May; 1687():66-73. PubMed ID: 29452071
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polymorphisms of Catechol-O-Methyl Transferase (COMT) Gene in Vulnerability to Levodopa-Induced Dyskinesia.
    Ivanova SA; Alifirova VM; Pozhidaev IV; Freidin MB; Zhukova IA; Osmanova DZ; Zhukova NG; Mironova YA; Tiguntsev VV; Fedorenko OY; Bokhan NA; Wilffert B; Loonen AJM
    J Pharm Pharm Sci; 2018; 21(1):340-346. PubMed ID: 30075828
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Parkinson's disease: levodopa-induced dyskinesia and signal transduction.
    Santini E; Valjent E; Fisone G
    FEBS J; 2008 Apr; 275(7):1392-1399. PubMed ID: 18279379
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alternative splicing of AMPA receptor subunits in the 6-OHDA-lesioned rat model of Parkinson's disease and L-DOPA-induced dyskinesia.
    Kobylecki C; Crossman AR; Ravenscroft P
    Exp Neurol; 2013 Sep; 247():476-84. PubMed ID: 23360800
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New insights into pathogenesis of l-DOPA-induced dyskinesia.
    Zheng C; Zhang F
    Neurotoxicology; 2021 Sep; 86():104-113. PubMed ID: 34331976
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sequence variants in SLC6A3, DRD2, and BDNF genes and time to levodopa-induced dyskinesias in Parkinson's disease.
    Kaplan N; Vituri A; Korczyn AD; Cohen OS; Inzelberg R; Yahalom G; Kozlova E; Milgrom R; Laitman Y; Friedman E; Rosset S; Hassin-Baer S
    J Mol Neurosci; 2014 Jun; 53(2):183-8. PubMed ID: 24633632
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.